ArticleCytotechnology2025
Exosomes carrying lncRNA FLG-AS1 overexpression vectors inhibit the tumorigenesis of oral squamous cell carcinoma via fat mass and obesity-associated protein-mediated m6A modification.
Article in Cytotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The impact of m6A modified cargo conveyed by exosomes on the tumor microenvironment.Discover oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Long noncoding RNAs (lncRNAs) selectively incorporated into exosomes contribute to the tumorigenesis of various cancers. However, the role of the lncRNA FLG-AS1 in oral squamous cell carcinoma (OSCC) has yet to be investigated. Hence, the current study aimed to evaluate the potential role of exosome-derived FLG-AS1 in OSCC. The expression of FLG-AS1 and fat mass and obesity-associated protein (FTO) in OSCC samples were determined via real-time quantitative polymerase chain reaction (RT-qPCR). The role of FLG-AS1 in OSCC was investigated by performing CCK8, flow cytometry, and transwell assays. Additionally, bioinformatics, methylated (m6A) RNA immunoprecipitation, and RT-qPCR were performed to evaluate the n6-methyladenosine (m6A) modification of FLG-AS1 and its underlying mechanism. Characterization of exosomal FLG-AS1 in OSCC cells was achieved through transmission electron microscopy, nanoparticle tracking analysis, Western blot analysis of CD63 and CD9, and RT-qPCR. Finally, the effects of exosomal FLG-AS1 on OSCC cell malignancy was analyzed using the aforementioned cell-based assays. Overall, our findings showed that low FLG-AS1 expression in OSCC restricted the malignant properties of OSCC cells. Furthermore, FTO reduced FLG-AS1 expression by mediating its m6A demethylation in OSCC cells. Exosomal FLG-AS1 expression was upregulated in OSCC cells, suggesting that it was packaged in the OSCC cell-derived exosomes, whereas exosome-derived FLG-AS1 overexpression vector reduced the malignant potential of the target OSCC cells. In conclusion, exosomal FLG-AS1 functions as a tumor suppressor in OSCC, while FTO can impair FLG-AS1 expression through m6A demethylation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.